Short answer
TANDEM DIABETES CARE INC (TNDM) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
TANDEM DIABETES CARE INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 sales $283.7M, up 14%, with international growth 26% versus U.S. growth 9%
- Gross margin 57%, up 270 basis points, while operating loss narrowed to $2.4M from $22.9M
- Adjusted EBITDA $18.0M, or 6% margin, versus $2.8M and 1% margin, signaling substantial operating leverage
- Pharmacy channel reached 15% of U.S. sales, with formulary coverage expanded to approximately 50% of U.S. lives
- 2026 guidance reaffirmed: sales $1.065B-$1.085B and adjusted EBITDA margin 5%-6%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TANDEM DIABETES CARE INC 8-K filings
Get the next TNDM 8-K as it lands
Follow TNDM for push alerts, or ask the research agent what this filing means.